XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and License Agreements (Details) $ in Thousands, € in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Feb. 28, 2019 USD ($) | Nov. 30, 2017 USD ($) | Oct. 31, 2017 USD ($) | Mar. 31, 2015 USD ($) | Oct. 31, 2014 USD ($) | Oct. 31, 2014 EUR (€) | Sep. 30, 2020 USD ($) | Dec. 31, 2019 USD ($) | Mar. 31, 2018 USD ($) | Mar. 31, 2017 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($)
Collaboration and License Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sanofi termination cash payment |  |  |  |  |  |  | $ 208,000 |  |  |  | $ 26,000 | $ 208,000 |  |
Sanofi Revenue Recognized |  |  |  |  |  |  |  |  |  |  | 286,000 | 286,000 |  |
Ipsen Total Payments |  |  |  |  |  |  | 47,200 |  |  |  | 47,200 |  |  |
Ipsen Maximum Regulatory And Commercial Milestones |  |  |  |  |  |  |  |  |  |  | 9,600 |  |  |
Ipsen Maximum Sales Milestones | € |  |  |  |  |  | € 72 |  |  |  |  |  |  |  |
Ipsen Total Upfront Payments |  |  |  | $ 24,500 |  |  |  |  |  |  |  |  |  |
Ipsen Milestone Payment |  |  |  |  |  |  |  |  |  | $ 6,400 |  |  |  |
Ipsen Milestone Payment Received | $ 2,300 | $ 3,800 | $ 3,800 |  |  |  |  | $ 1,300 | $ 5,100 |  |  |  |  |
Ipsen Revenue Allocated to License Deliverable |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400 | $ 21,200
Ipsen Revenue Allocated to Development Deliverable |  |  |  |  | $ 1,700 |  |  |  |  |  |  |  |  |
Ipsen Revenue Allocated to Committee Deliverable |  |  |  |  | $ 100 |  |  |  |  |  |  |  |  |
Ipsen Revenue Recognized |  |  |  |  |  |  |  |  |  |  | 300 | $ 3,500 |  |
lxrx_sanofi initial cash payment |  |  |  |  |  |  | $ 26,000 |  |  |  | 26,000 |  |  |
Ipsen Royalty Income_LXRX |  |  |  |  |  |  |  |  |  |  | $ 300 |  |  |

X
- Definition Collaboration and License Agreements [Abstract] + References No definition available. + Details
Name: | lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix: | lxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumRegulatoryAndCommercialMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumSalesMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenMilestonePayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period. + References No definition available. + Details
Name: | lxrx_IpsenMilestonePaymentReceived
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_IpsenRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S. + References No definition available. + Details
Name: | lxrx_IpsenRoyaltyIncome_LXRX
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenTotalPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenTotalUpfrontPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance + References No definition available. + Details
Name: | lxrx_Lxrx_Sanofiterminationcashpayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition lxrx_sanofi initial cash payment + References No definition available. + Details
Name: | lxrx_Lxrx_sanofiInitialCashPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_SanofiRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration